Literature DB >> 12128152

Sphingomyelinase and ceramide analogs induce vasoconstriction and leukocyte-endothelial interactions in cerebral venules in the intact rat brain: Insight into mechanisms and possible relation to brain injury and stroke.

Burton M Altura1, Asefa Gebrewold, Tao Zheng, Bella T Altura.   

Abstract

This study was designed to test the hypothesis that the sphingomyelin-ceramide signaling pathway may be important in proinflammatory-like responses in the intact brain. Effects of neutral sphingomyelinase (N-SMase), ceramide analogs, phosphorylcholine and ceramide metabolites were studied on rat brain cerebral (cortical) venule lumen sizes, leukocyte rolling, velocity and endothelial cell wall adhesion, microvessel permeability, microvessel rupture and focal hemorrhages using in vivo high resolution TV microscopy. Perivascular and close intra-arterial administration of N-SMase, C(2)-, C(8)-, and C(16)-ceramide, but not either phosphorylcholine, C(6)-ceramide, nervonic (C(24):1) ceramide, lignoceric (C(24):0) ceramide, C(8)-ceramide-1-phosphate, glucosylceramide or 1-0-acylceramide, resulted in potent, concentration-dependent constriction (and spasm) of cortical venules, followed by increased leukocyte rolling, decreased leukocyte velocities, increased leukocyte-endothelial wall adhesion, increased venular wall permeability, postcapillary venule rupture and, often, micro-hemorrhaging at high concentrations; angiotensin II, serotonin and PGF(2alpha) didn't demonstrate these characteristics. Pretreatment with either one of three different antioxidants, including inhibitors of NF-kappaB activation, or two different Ca(2+) channel blockers either prevented or attenuated the adverse venular effects of N-SMase and the ceramides. Likewise, pretreatment with either a PKCalpha-beta antagonist or a MAP kinase antagonist also attenuated the adverse venular effects. These results suggest that N-SMase and several ceramides can result in potent venular cerebrovasospasm, leukocyte-endothelial chemoattraction, and microvessel wall permeability changes in the intact rat brain. These proinflammatory-like actions suggest that N-SMase and ceramides could produce brain-vascular damage by reperfusion injury triggering lipid peroxidation, release of reactive oxygen species and activation of diverse signaling pathways: PKCalpha-beta isozymes, MAP kinase and NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12128152     DOI: 10.1016/s0361-9230(02)00772-4

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  13 in total

1.  Mass spectrometry imaging of rat brain lipid profile changes over time following traumatic brain injury.

Authors:  Aurelie Roux; Ludovic Muller; Shelley N Jackson; Jeremy Post; Katherine Baldwin; Barry Hoffer; Carey D Balaban; Damon Barbacci; J Albert Schultz; Shawn Gouty; Brian M Cox; Amina S Woods
Journal:  J Neurosci Methods       Date:  2016-02-10       Impact factor: 2.390

2.  Mg deficiency results in modulation of serum lipids, glutathione, and NO synthase isozyme activation in cardiovascular tissues: relevance to de novo synthesis of ceramide, serum Mg and atherogenesis.

Authors:  Nilank C Shah; Jian-Ping Liu; Jahangir Iqbal; Mahmood Hussain; Xian-Cheng Jiang; Zhiqiang Li; Yan Li; Tao Zheng; Wenyan Li; Anthony C Sica; Jose Luis Perez-Albela; Bella T Altura; Burton M Altura
Journal:  Int J Clin Exp Med       Date:  2011-04-05

3.  Short-term Mg deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells; relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review.

Authors:  Burton M Altura; Nilank C Shah; Gatha J Shah; Aimin Zhang; Wenyan Li; Tao Zheng; Jose Luis Perez-Albela; Bella T Altura
Journal:  Int J Clin Exp Med       Date:  2014-01-15

4.  Changes in the metabolism of sphingolipids after subarachnoid hemorrhage.

Authors:  Fernando D Testai; Hao-Liang Xu; John Kilkus; Vidyani Suryadevara; Irina Gorshkova; Evgeny Berdyshev; Dale A Pelligrino; Glyn Dawson
Journal:  J Neurosci Res       Date:  2015-01-19       Impact factor: 4.164

5.  Short-term magnesium deficiency upregulates sphingomyelin synthase and p53 in cardiovascular tissues and cells: relevance to the de novo synthesis of ceramide.

Authors:  Burton M Altura; Nilank C Shah; Zhiqiang Li; Xian-Cheng Jiang; Aimin Zhang; Wenyan Li; Tao Zheng; Jose Luis Perez-Albela; Bella T Altura
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-08       Impact factor: 4.733

6.  Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium.

Authors:  Daniel Serrano; Tridib Bhowmick; Rishi Chadha; Carmen Garnacho; Silvia Muro
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-02-09       Impact factor: 8.311

Review 7.  Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis.

Authors:  Linda Sasset; Yi Zhang; Teresa M Dunn; Annarita Di Lorenzo
Journal:  Trends Endocrinol Metab       Date:  2016-08-22       Impact factor: 12.015

8.  Induction by sphingomyelinase of shiga toxin receptor and shiga toxin 2 sensitivity in human microvascular endothelial cells.

Authors:  T G Obrig; R M Seaner; M Bentz; C A Lingwood; B Boyd; A Smith; W Narrow
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

9.  Magnesium deficiency upregulates sphingomyelinases in cardiovascular tissues and cells: cross-talk among proto-oncogenes, Mg(2+), NF-κB and ceramide and their potential relationships to resistant hypertension, atherogenesis and cardiac failure.

Authors:  Burton M Altura; Nilank C Shah; Gatha J Shah; Wenyan Li; Aimin Zhang; Tao Zheng; Zhiqiang Li; Xian-Cheng Jiang; Jose Luis Perez-Albela; Bella T Altura
Journal:  Int J Clin Exp Med       Date:  2013-10-25

Review 10.  Cerebral venous collaterals: A new fort for fighting ischemic stroke?

Authors:  Lu-Sha Tong; Zhen-Ni Guo; Yi-Bo Ou; Yan-Nan Yu; Xiao-Cheng Zhang; Jiping Tang; John H Zhang; Min Lou
Journal:  Prog Neurobiol       Date:  2017-12-02       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.